US4751221A
(en)
*
|
1985-10-18 |
1988-06-14 |
Sloan-Kettering Institute For Cancer Research |
2-fluoro-arabinofuranosyl purine nucleosides
|
US5310732A
(en)
*
|
1986-02-03 |
1994-05-10 |
The Scripps Research Institute |
2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
|
US5106837A
(en)
*
|
1988-03-16 |
1992-04-21 |
The Scripps Research Institute |
Adenosine derivatives with therapeutic activity
|
IL84842A0
(en)
*
|
1986-12-24 |
1988-06-30 |
Lilly Co Eli |
Immunoglobulin conjugates
|
US5175274A
(en)
*
|
1987-04-03 |
1992-12-29 |
Burroughs Wellcome Co. |
Therapeutic nucleosides
|
GB8708050D0
(en)
*
|
1987-04-03 |
1987-05-07 |
Wellcome Found |
Therapeutic nucleosides
|
US5459256A
(en)
*
|
1987-04-17 |
1995-10-17 |
The Government Of The United States Of America As Represented By The Department Of Health And Human Services |
Lipophilic, aminohydrolase-activated prodrugs
|
US5495010A
(en)
*
|
1987-04-17 |
1996-02-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Acid stable purine dideoxynucleosides
|
DE68924319T2
(de)
*
|
1988-03-16 |
1996-05-15 |
Scripps Research Inst |
Als therapeutische mittel verwendbare substituierte adeninderivate.
|
GB8815241D0
(en)
*
|
1988-06-27 |
1988-08-03 |
Wellcome Found |
Antiviral combinations & compounds therefor
|
GB8816345D0
(en)
*
|
1988-07-08 |
1988-08-10 |
Hoffmann La Roche |
Purine derivatives
|
US5026688A
(en)
*
|
1988-10-31 |
1991-06-25 |
Administrators Of The Tulane Educational Fund |
Novel AZT analogs
|
US5034518A
(en)
*
|
1989-05-23 |
1991-07-23 |
Southern Research Institute |
2-fluoro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine nucleosides
|
US5384310A
(en)
*
|
1989-05-23 |
1995-01-24 |
Southern Research Institute |
2'-fluoro-2-haloarabinoadinosines and their pharmaceutical compositions
|
GB8920534D0
(en)
*
|
1989-09-11 |
1989-10-25 |
Wellcome Found |
Antiviral compounds
|
HU906976D0
(en)
*
|
1989-11-13 |
1991-05-28 |
Bristol Myers Squibb Co |
Process for producing 2', 3'-didesoxy-2'-fluoarabinonucleoside analogues
|
US5681941A
(en)
*
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
AU7558491A
(en)
*
|
1990-04-04 |
1991-10-30 |
Nycomed Imaging As |
Nucleoside derivatives
|
US5817799A
(en)
*
|
1990-07-23 |
1998-10-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides
|
US5420115A
(en)
*
|
1990-09-10 |
1995-05-30 |
Burroughs Wellcome Co. |
Method for the treatment of protoza infections with 21 -deoxy-21 -fluoropurine nucleosides
|
AU1254892A
(en)
*
|
1990-12-18 |
1992-07-22 |
Sloan-Kettering Institute For Cancer Research |
Novel synthesis of 2'-"up" fluorinated 2''-deoxy-arabinofuranosylpurines
|
US5672697A
(en)
*
|
1991-02-08 |
1997-09-30 |
Gilead Sciences, Inc. |
Nucleoside 5'-methylene phosphonates
|
JPH07507775A
(ja)
*
|
1992-05-19 |
1995-08-31 |
ザ スクリップス リサーチ インスティテュート |
慢性骨髄性白血病の治療薬としての2−ハロアデニン誘導体の使用
|
US5371210A
(en)
*
|
1992-06-22 |
1994-12-06 |
Eli Lilly And Company |
Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
US5606048A
(en)
*
|
1992-06-22 |
1997-02-25 |
Eli Lilly And Company |
Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
US5401838A
(en)
*
|
1992-06-22 |
1995-03-28 |
Eli Lilly And Company |
Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
US5594124A
(en)
*
|
1992-06-22 |
1997-01-14 |
Eli Lilly And Company |
Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
|
US5426183A
(en)
*
|
1992-06-22 |
1995-06-20 |
Eli Lilly And Company |
Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
CZ123493A3
(en)
*
|
1992-06-22 |
1994-02-16 |
Lilly Co Eli |
Stereoselective anionic glycosylation process
|
US5821357A
(en)
*
|
1992-06-22 |
1998-10-13 |
Eli Lilly And Company |
Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
|
US5602246A
(en)
*
|
1992-11-25 |
1997-02-11 |
Schering Aktiengesellschaft |
Process for the preparation of fludarabine or fludarabine phosphate from guanosine
|
US5424416A
(en)
*
|
1993-08-25 |
1995-06-13 |
Eli Lilly And Company |
Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
|
US6491905B1
(en)
*
|
1993-09-14 |
2002-12-10 |
The Uab Research Foundation |
Recombinant bacterial cells for delivery of PNP to tumor cells
|
US5525606A
(en)
|
1994-08-01 |
1996-06-11 |
The United States Of America As Represented By The Department Of Health And Human Services |
Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
|
US5641757A
(en)
*
|
1994-12-21 |
1997-06-24 |
Ortho Pharmaceutical Corporation |
Stable 2-chloro-2'-deoxyadenosine formulations
|
US6232463B1
(en)
|
1997-10-09 |
2001-05-15 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
JPH11217396A
(ja)
*
|
1998-01-30 |
1999-08-10 |
Ajinomoto Co Inc |
ヌクレオシド誘導体の製造方法
|
US6060458A
(en)
*
|
1998-02-13 |
2000-05-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Oligodeoxyribonucleotides comprising O6 -benzylguanine and their use
|
AU2005234681B2
(en)
*
|
2000-02-18 |
2008-11-20 |
Southern Research Institute |
Methods for Synthesizing 2-Chloro-9-(2-Deoxy-2-Fluoro-Beta-D-Arabinofuranosyl)-9H-Purin-6-Amine
|
AU2001238516B2
(en)
*
|
2000-02-18 |
2005-08-04 |
Southern Research Institute |
Methods for synthesizing 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H- purin-6-amine
|
US7528247B2
(en)
*
|
2001-08-02 |
2009-05-05 |
Genzyme Corporation |
Process for preparing purine nucleosides
|
DE60226447D1
(de)
|
2001-08-02 |
2008-06-19 |
Ilex Oncology Inc |
Verfahren zur herstellung von purinnukleosiden
|
US7022680B2
(en)
*
|
2002-05-30 |
2006-04-04 |
Albert Einstein College Of Medicine Of Yeshiva University |
Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
|
EP1549141A4
(de)
*
|
2002-09-27 |
2008-06-25 |
Bioenvision Inc |
Verfahren und zusammensetzungen für die behandlung von autoimmunerkrankungen unter verwendung von clofarabin
|
WO2004028463A2
(en)
*
|
2002-09-27 |
2004-04-08 |
Bioenvision, Inc. |
Methods and compositions for the treatment of lupus using clofarabine
|
EP1460082A1
(de)
|
2003-03-19 |
2004-09-22 |
Heidelberg Pharma Holding GmbH |
Phospholipidester von clofarabin-derivate
|
US7273600B2
(en)
*
|
2003-04-25 |
2007-09-25 |
University Of Southern California |
[18F]-furanosylpurine derivatives and uses thereof
|
CA2542915A1
(en)
*
|
2003-10-24 |
2005-05-06 |
Yamasa Corporation |
.alpha.-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-.beta.-d-arabinonucleoside
|
WO2006015346A1
(en)
*
|
2004-07-30 |
2006-02-09 |
Pharmaessentia Corp. |
STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
|
US7485716B2
(en)
*
|
2005-05-02 |
2009-02-03 |
Pharmaessentia Corp. |
Stereoselective synthesis of β-nucleosides
|
WO2007027564A2
(en)
*
|
2005-08-29 |
2007-03-08 |
Chemagis Ltd. |
Process for preparing gemcitabine and associated intermediates
|
US20070191598A1
(en)
*
|
2006-02-07 |
2007-08-16 |
Chemagis Ltd. |
Process for Preparing Gemcitabine and Associated Intermediates
|
US20070249823A1
(en)
*
|
2006-04-20 |
2007-10-25 |
Chemagis Ltd. |
Process for preparing gemcitabine and associated intermediates
|
JP5421098B2
(ja)
*
|
2006-06-06 |
2014-02-19 |
ジーアイケア ファーマ インク. |
トリメブチン及びn−脱メチル化トリメブチンの塩類
|
US20080262215A1
(en)
*
|
2007-04-23 |
2008-10-23 |
Chemagis Ltd. |
Gemcitabine production process
|
US8741858B2
(en)
|
2007-09-21 |
2014-06-03 |
Zhongxu Ren |
Oligomer-nucleoside phosphate conjugates
|
US8193339B2
(en)
*
|
2007-11-06 |
2012-06-05 |
Pharmaessentia Corp. |
Synthesis of β-nucleosides
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
ES2341215B1
(es)
*
|
2008-12-15 |
2011-04-26 |
Consejo Superior De Investigaciones Cientificas (Csic) (51%) |
Nucleosidos modificados para el tratamiento de infecciones por leishmania.
|
ES2341603B1
(es)
*
|
2008-12-15 |
2011-04-28 |
Consejo Superior De Investigaciones Cientificas (Csic) (51%) |
Derivados de nucleosidos para el tratamiento de infecciones por leishmania.
|
CL2009002206A1
(es)
|
2008-12-23 |
2011-08-26 |
Gilead Pharmasset Llc |
Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
|
NZ593648A
(en)
|
2008-12-23 |
2013-09-27 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
EA201100851A1
(ru)
|
2008-12-23 |
2012-04-30 |
Фармассет, Инк. |
Аналоги нуклеозидов
|
EP2410987B1
(de)
*
|
2009-03-23 |
2018-05-16 |
Ambit Biosciences Corporation |
Behandlungsverfahren mit kombinationstherapien
|
BRPI1010809A2
(pt)
*
|
2009-05-12 |
2015-10-13 |
Southern Res Inst |
composto, composição farmacêutica, métodos de tratar câncer em mamífero e usos de compostos e de composição farmacêutica
|
US9790252B2
(en)
|
2009-07-01 |
2017-10-17 |
Cornell University |
2-fluorinated riboses and arabinoses and methods of use and synthesis
|
US9011817B2
(en)
*
|
2009-09-03 |
2015-04-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compounds and methods of making compounds
|
BR112012024884A2
(pt)
|
2010-03-31 |
2016-10-18 |
Gilead Pharmasset Llc |
síntese estereosseletiva de ativos contendo fósforo
|
CN102311472B
(zh)
|
2010-07-09 |
2014-09-03 |
神隆(昆山)生化科技有限公司 |
2-氯-9-(2’-脱氧-2’-氟-β-D-阿拉伯呋喃糖基)-腺嘌呤的制备
|
CN104193790A
(zh)
*
|
2014-09-25 |
2014-12-10 |
王庚禹 |
一种甲酰腺嘌呤化合物
|
PL3661937T3
(pl)
|
2017-08-01 |
2021-12-20 |
Gilead Sciences, Inc. |
Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
|